TABLE 2.
A summary of the health implications of betaine with molecular mechanisms.
| Disease | Effect of betaine | Molecular mechanism | References |
|---|---|---|---|
| Homocystinuria | Lowers plasma tHcy levels | Promotion of methionine-homocysteine cycle | Craig (2004) |
| Cardiovascular disease | Lowers plasma tHcy levels | Promotion of methionine-homocysteine cycle | Schwab et al. (2006), Olthof et al. (2016) |
| Reduction of inflammation | Lowers the C-reactive protein, IL-6, and TNF-α | Detopoulou et al. (2008), Lv et al. (2009) | |
| Liver disease (Alcoholic and non-alcoholic fatty liver disease) | Suppresses hepatic lipid synthesis | suppression of DGAT1, DGAT2, SREBP-1c, SREBP-2, fatty acid synthase, and HMG-CoA reductase and upregulation of PGC-1α in the liver | Yang et al. (2017) |
| Enhances fatty acid oxidation | Increase of the expression of CPT1, PPARα, FGF21, and AMPK in the liver | Li et al. (2015b) | |
| Promotes VLDL synthesis and release | Increase of hepatic SAM/SAH ratio and promotes one-carbon metabolism and synthesis of phosphatidylcholine | Barak et al. (1997), Deminice et al. (2015) | |
| Enhances BHMT expression and promotion of hepatic PC synthesis | Li et al. (2015b) | ||
| Alleviates hyperhomocysteinemia | Promotion of methionine-homocysteine cycle | Kenyon et al. (1998), Stickel et al. (2000) | |
| Reduction of oxidative stress | Increase in cellular reduced glutathione levels | Jung et al. (2013), Zakhari (2013), Kim et al. (2017) | |
| Reduces ER stress | Attenuation of GRP78, CHOP, and JNK activation | Kaplowitz and Ji (2006), Wang et al. (2010) | |
| Inhibition of inflammatory response | Suppression of NLRP3 inflammasome activation | Kim et al. (2017) | |
| Inhibition of IL-1β production and release | Xia et al. (2018), Zhao et al. (2018) | ||
| Induction of IL-10 and decreasing TNF and IL-6 expression | Veskovic et al. (2019) | ||
| Improves adipocyte functions | Increase in mitochondrial biogenesis | Du et al. (2018) | |
| Corrects aberrant adipokine production | Wang et al. (2010) | ||
| Improves insulin resistance | Activation of IRS1, PKB/Akt, and AMPK | Kathirvel et al. (2010); Du et al. (2018) | |
| Modulate epigenetic modifications | Increase of SAM/SAH ratio and restore methylation capacity; Downregulation of fatty acid synthase and upregulation of fatty acid oxidation (ACOX, PPARα, AMPK, FGF10, ATGL) | Wang et al. (2014); Chen et al. (2021) | |
| Increase in mitochondrial content and activity | Zhang et al. (2019) | ||
| Inhibits apoptosis | Reduction of Bax and induction of Bcl-2 | Veskovic et al. (2019) | |
| Activation of Akt/mTOR signaling | Veskovic et al. (2019) | ||
| Activates autophagy | Increases the expression of beclin 1, Atg4, and Atg5 | Veskovic et al. (2019) | |
| Neurological disorders | Enhances neuronal mitochondrial respiration | Modulation of histone H3 trimethylation on Lys 4 (H3K4me3) in neurons | Singhal et al. (2020) |
| Promotes oligodendrocyte maturation | Modulation of DNA methylation and increases the expression of oligodendrocyte maturation genes SOX10 and NKX-2.2 | Sternbach et al. (2021) | |
| Prevents oxidative stress | Enhancement of glutathione peroxidase activity | Alirezaei et al. (2011) | |
| Mitigates hyperhomocysteinemia in Alzheimer’s disease | Attenuation of tau hyperphosphorylation and Aβ production | Chai et al. (2013) |